ArticleAnnals of translational medicine2022
Factors predicting the occurrence of net adverse clinical and cerebral events in patients with acute coronary syndrome treated with clopidogrel or ticagrelor in combination with aspirin: a real-world study.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Prognostic value of elevated postoperative high-sensitivity troponin T in diabetes mellitus patients for ischemic events within 12 months after PCI in ACS patients: a retrospective cohort study.Frontiers in cardiovascular medicine · 2025Article
- Risk factors for heart failure within one year after percutaneous coronary intervention in patients with acute coronary syndrome: development of a predictive model.American journal of translational research · 2025Article
- Clopidogrel-loaded vascular grafts prepared using digital light processing 3D printing.Drug delivery and translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to establish the factors influencing the clinical benefits of ticagrelor and clopidogrel for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) surgery. Methods: A multicenter, retrospective, real-world study was conducted on patients with ACS whose data were sourced from 3 databases, namely the BRIC-ACS(I) study, COSTIC study, and 301 Hospital PCI patient database from January 2014 to October 2017. The primary endpoint was net adverse clinical and cerebral events (NACCE). Results: A total of 7,236 ACS patients were included, of which 4,444 patients (61.4%) and 2,792 patients (38.6%) were in the clopidogrel dual antiplatelet therapy (DAPT) group and ticagrelor DAPT group, respectively. The hazard ratio (HR) for NACCE was significantly higher in patients aged ≥65 years than those aged ≤65 years in the clopidogrel DAPT group (HR: 2.15, 95% CI: 1.68-2.76) and ticagrelor DAPT group (HR: 1.75, 95% CI: 1.34-2.29). In patients treated with clopidogrel DAPT, patients with unstable angina had a significantly lower HR for NACCE than patients with ST-elevation myocardial infarction. Use of beta blockers (HR: 0.77, 95% CI: 0.60-0.99) was an influencing factor in patients treated with clopidogrel DAPT, whereas in patients treated with ticagrelor DAPT, only smoking status (HR: 0.75, 95% CI: 0.57-0.99) was a significant influencing factor. Conclusions: Age, hypertension status, and presence or absence of unstable angina were factors influencing the composite outcome of NACCE. The selection of patients to be treated with either clopidogrel DAPT or ticagrelor DAPT depending on the presence or absence of factors influencing treatment outcome may improve therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.